Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 949-982
Open Access | Times Cited: 172

Showing 1-25 of 172 citing articles:

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Christopher Tay, Atsushi Tanaka, Shimon Sakaguchi
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 450-465
Open Access | Times Cited: 259
Chronic inflammation, cancer development and immunotherapy
Yalei Wen, Ying‐Jie Zhu, Caishi Zhang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 99
Cadonilimab: First Approval
Susan J. Keam
Drugs (2022) Vol. 82, Iss. 12, pp. 1333-1339
Closed Access | Times Cited: 88
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
Cancer immune escape: the role of antigen presentation machinery
Anoop Kallingal, Mateusz Olszewski, Natalia Maciejewska, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 8131-8141
Open Access | Times Cited: 63
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Mateusz Kciuk, Esam Bashir Yahya, Montaha Mohamed Ibrahim Mohamed, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2721-2721
Open Access | Times Cited: 53
The future of cancer immunotherapy: DNA vaccines leading the way
Aanshi J. Pandya, Yesha Shah, Nirjari Kothari, et al.
Medical Oncology (2023) Vol. 40, Iss. 7
Open Access | Times Cited: 42
Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy
Ryungsa Kim, Takanori Kin, William T. Beck
Cancers (2024) Vol. 16, Iss. 5, pp. 984-984
Open Access | Times Cited: 21
Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review
Aleksandra Golonko, Tomasz Pienkowski, Renata Świsłocka, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 19
Targeting p53 for Immune Modulation: Exploring Its Functions in Tumor Immunity and Inflammation
Hong Wu, Sarah Leng, David D. Eisenstat, et al.
Cancer Letters (2025), pp. 217614-217614
Closed Access | Times Cited: 2
The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer
Azin Aghamajidi, Saman Maleki Vareki
Cancers (2022) Vol. 14, Iss. 15, pp. 3563-3563
Open Access | Times Cited: 56
Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy
Yurong Qin, Miaozhe Huo, Xingwu Liu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 14
Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy
Shivi Chauhan, Shivani Jaiswal, Vibhuti Jakhmola, et al.
Cancer Letters (2024) Vol. 588, pp. 216766-216766
Open Access | Times Cited: 12
Advances of Layered Double Hydroxide‐Based Materials for Tumor Imaging and Therapy
Ke Ma, Kezheng Chen, Sheng‐Lin Qiao
The Chemical Record (2024) Vol. 24, Iss. 4
Closed Access | Times Cited: 11
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect
Conghua Lu, Ziyuan Gao, Di Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009165-e009165
Open Access | Times Cited: 10
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Pankaj Kumar Garg, Siddhika Pareek, Prakash Kulkarni, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6537-6537
Open Access | Times Cited: 9
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain
International Immunopharmacology (2024) Vol. 143, pp. 113365-113365
Closed Access | Times Cited: 8
Microenvironment-based immunotherapy in oral cancer: a comprehensive review
Hassan Mivehchi, Aisan Eskandari-Yaghbastlo, Masumeh Ghazanfarpour, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access | Times Cited: 1
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Xinming Li, Mingdong Li, Meiying Huang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 113064-113064
Open Access | Times Cited: 33
Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
Aiswarya Chaudhuri, Dulla Naveen Kumar, Deepa Dehari, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 542-542
Open Access | Times Cited: 32
Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
Xia Qiu, Tianjiao Zhao, Ran Luo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 29
Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer
Yingying Yu, Siyu Wang, Nan Su, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 29
Recent Advances in Cancer Immunotherapy Delivery Modalities
Palaniyandi Muthukutty, Hyun Young Woo, Murali Ragothaman, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 504-504
Open Access | Times Cited: 19
Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
Nathanael J. Bangayan, Liang Wang, Giselle Burton Sojo, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 47
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top